PacBio logo

PacBio Stock

StockStock
ISIN: US69404D1081
Ticker: PACB
US69404D1081
PACB

Price

Frequently asked questions

What is PacBio's market capitalization?

The market capitalization of PacBio is $591.39M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for PacBio?

PacBio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.495. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for PacBio's stock?

Currently, 15 analysts cover PacBio's stock, with a consensus target price of $3.333. Analyst ratings provide insights into the stock's expected performance.

What is PacBio's revenue over the trailing twelve months?

Over the trailing twelve months, PacBio reported a revenue of $188.87M.

What is the EBITDA for PacBio?

PacBio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$286.45M. EBITDA measures the company's overall financial performance.

What is the free cash flow of PacBio?

PacBio has a free cash flow of -$260.90M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of PacBio's stock?

The 5-year beta for PacBio is 2.01. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does PacBio have, and what sector and industry does it belong to?

PacBio employs approximately 796 people. It operates in the Health Care sector, specifically within the Medical Equipment & Supplies industry.

What is the free float of PacBio's shares?

The free float of PacBio is 267.39M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$591.39M

5Y beta

 
2.01

EPS (TTM)

 
-$1.495

Free Float

 
267.39M

Revenue (TTM)

 
$188.87M

EBITDA (TTM)

 
-$286.45M

Free Cashflow (TTM)

 
-$260.90M

Pricing

52W span
$1.16$10.65

Analyst Ratings

The price target is $3.333 and the stock is covered by 15 analysts.

Buy

7

Hold

8

Sell

0

Information

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

796

Medical Equipment & Supplies

Health Care

Identifier

ISIN

US69404D1081

Primary Ticker

PACB

Knockouts

Join the conversation